Takeda Gains On Sanofi As Two-Shot Dengue Vaccine Advances
While Sanofi late last year became the first company to commercialize a vaccine for dengue, Takeda has strengthened its position as the likely next to market contender following the start of a global Phase III program for its rival product.
You may also be interested in...
India’s ‘Cautious’ View Dulls Sanofi Hopes For Early Dengvaxia Launch
An early rollout of Sanofi Pasteur’s dengue vaccine in India is looking less likely with a senior functionary of the health ministry telling Scrip why India needs to take a “cautious view” on the product’s licensure in the country, at least for now. Sanofi, though, has sought the “best regulatory solution” that can facilitate access to the product.
Sun Dips Toe Into Vaccines With Dengvaxia Challenge
India's top-ranked drug firm Sun Pharma is vying for a play in the dengue vaccines space via a collaboration with the non-profit research organization, International Centre for Genetic Engineering and Biotechnology. The partners expect their vaccine candidate to potentially best live-attenuated dengue vaccine candidates, including Sanofi's Dengvaxia.
Takeda In Hot Pursuit Of Zika Vaccine With $312m US Contract
Takeda is officially in the ballgame, joining the ranks of other firms like Sanofi Pasteur and GlaxoSmithKline, to find a vaccine against the Zika virus after snagging a US government R&D contract worth up to $312m.